Your Position: Home > Journal List > CHINA MEDICINE > Paper

Observation of domestic docetaxel in the first line treatment of elderly patients with advanced non-small cell lung cancer

( views:, downloads: )
Author:
MU Ling(Oncological Department,Rizhao People Hospital,Rizhao 276826,China)
MENG Ling-xin(Oncological Department,Rizhao People Hospital,Rizhao 276826,China)
YIN Qiang(Oncological Department,Rizhao People Hospital,Rizhao 276826,China)
LI Yu-feng(Oncological Department,Rizhao People Hospital,Rizhao 276826,China)
LIU Shan(Oncological Department,Rizhao People Hospital,Rizhao 276826,China)
LI Ming-huan(Oncological Department,Rizhao People Hospital,Rizhao 276826,China)
Journal Title:
CHINA MEDICINE
Issue:
Volume 5, Issue 02, 2010
DOI:
10.3760/cma.j.issn.1673-4777.2010.02.002
Key Word:
Lung neoplasms;Elderly non-small cell lung cancer;Docetaxel;First line therapy

Abstract: Objective To observe the efficacy of domestic docetaxel in the first line treatment of 72 cases elderly patients with advanced non-small cell lung cancer (NSCLC). Methods Totally 72 elderly patients with NSCLC were treated with domestic docetaxel with a dose of 50~60 mg/m~2 on day 1 and day 8. Re-evaluation was done after every two cycles. Those who did not have tumor progression went through other two cycles of chemotherapy and all patients were followed up until disease progressed or patients died. Results Seventy-two patients were eval-uated and shoured 26.4% response rate, 52.8% stable disease,3.2 months of median progression free survival (PFS), 8.4 months of median OS and 33.9%, 18.6% 1-year,2-year survival rate, respectively. Female patients had better outcomes than the male. Patients with good performance status(PS) had better results than those without good PS. Patients with stage Ⅲ B had better results than stage Ⅳ and those with less co-morbidities had better re-suits than those with more internal illness in subgroup analysis. There was statistical significance among different gender, performance status and clinical stage in terms of overall survival(P<0.05). The common adverse events were neutropenia(52.78%), asthenia(36.11%) and alopecia(43.06%). Conclusion Domestic docetaxel is an effective first line treatment for elderly patients with advanced NSCLC.

  • [1]Georgoulias V,Ardavanis A,Agelidou A,et al.Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer:a randomized,muhicenter phase Ⅲ trial.J Clin Oncol,2004,22 (13):2602-2609.
  • [2]Gridelli C,Shepherd FA.Chemotherapy for elderly Patients with non-small cell lung cancer:A review of the evidence.Chest,2005,128(2):947-957.
  • [3]Belani CP,Fossella F.Elderly subgroup analysis of a randomized phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first line treatment of advanced non small cell lung carcinoma (TAX326).Cancer,2005,104 (12):2766-2774.
  • [4]Simon GR,Extermann M,Chiappori A,et al.Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer(NSCLC) who are 70 years of age or older.Cancer,2008,112(9):2021-2029.
  • [5]Saloustros E,Georgoulias V.Docetaxel in the treatment of advanced non-small-cell lung cancer.Expert Rev Anticancer Ther,2008,8 (8):1207-1222.
  • [6]Horn L,Visbal A,Leighl NB.Docetaxel in non-small cell lung cancer:impact on quality of life and pharmacoeconomica.Drugs Aging,2007,24(5):411-428.
  • [7]蔡欣,胡冬梅,屈虹,等.多西他赛一线治疗老年晚期非小细胞肺癌的临床观察.临床肿瘤学杂志,2007,12(5):369-371.
  • [8]Ettinger DS,Beplor G,Bueno R,et al.Non-small cell lung cancer clinical practice guidelines in oncolngy.J Natl Compr Canc Netw,2006,4(6):548-582.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn